Abdi Ibrahim

Executive Summary

Abdi İbrahim, founded in 1912 and headquartered in Istanbul, is a leading Turkish pharmaceutical company and one of the oldest in the region. The company is fully integrated and commercial-stage, focusing on the development, manufacturing, and marketing of small molecule drugs across a broad range of therapeutic areas. With a strong commitment to healthcare, as reflected in its slogan 'Our job is to heal,' Abdi İbrahim serves both the Turkish market and international markets, positioning itself as a key player in the regional pharmaceutical landscape. The company operates as a private entity with a long track record of stability and market presence, benefiting from Turkey's growing healthcare sector and its own established distribution network. While not a high-growth biotech, Abdi İbrahim's diversified portfolio and steady operations provide a solid foundation for sustained performance, though it faces competition from both local and multinational firms.

Upcoming Catalysts (preview)

• Q1 2027Expansion into European Union markets via new product registrations75% success
• Q3 2026Launch of a new generic drug in the Turkish market85% success
• Q4 2026Strategic partnership or licensing deal for innovative small molecule assets65% success